Skip to main content
Clinical Trials/NCT00501514
NCT00501514CompletedPhase 3

Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients With Chronic Heart Failure

Federico II University1 site in 1 country22 target enrollmentStarted: November 1, 1997Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
22
Locations
1
Primary Endpoint
The primary outcome of the study was improvement of peak VO2 assessed by a cardiopulmonary exercise testing.

Study Overview

Brief Summary

The purpose of this study was to assess whether Growth Hormone(GH)improves exercise capacity and cardiopulmonary performance in patients with chronic heart failure.

Detailed Description

clinical studies have focused the effects of GH on left ventricular function and hemodynamics. Little is known about the impact of GH on cardiopulmonary performance and exercise capacity. Such data would be relevant, given the well-recognized importance of cardiopulmonary performance and exercise capacity as markers of disease progression and predictors of mortality in patients with CHF.Consequently we conducted a randomised double blind placebo controlled trial to investigate the effects of a three month course of GH, adjunctive to background therapy, on cardiopulmonary performance and exercise capacity in patients with dilated cardiomyopathy and CHF.The primary outcome of the study was improvement of peak VO2 assessed by a cardiopulmonary exercise testing. Secondary endpoints were exercise capacity and ejection fraction obtained by echocardiography.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Ejection fraction < 40%
  • •Left ventricular internal dimension >58 mm
  • •II-III NYHA class
  • •Stable hemodynamic condition during the previous three months
  • •Sinus rhythm

Exclusion Criteria

  • •IMA or CABG or PTCA in the previous six months
  • •Instable angina
  • •Major arrhythmias (Lown class> IV)
  • •Diseases limiting exercise capacity
  • •Insulin treated diabetes mellitus

Outcomes

Primary Outcomes

The primary outcome of the study was improvement of peak VO2 assessed by a cardiopulmonary exercise testing.

Time Frame: three months

Secondary Outcomes

  • Secondary endpoints were exercise capacity and ejection fraction obtained by echocardiography.(three months)

Investigators

Sponsor
Federico II University
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials